Page 25 - Read Online

14. Klaunig JE, Kamendulis LM. The role of oxidative stress in carcinogenic and chemopreventive agents. Front Biosci (Schol Ed)
carcinogenesis. Annu Rev Pharmacol Toxicol 2004;44:239-67. 2009;1:45-60.
15. Pang R, Tse E, Poon RT. Molecular pathways in hepatocellular 35. Shishodia S, Amin HM, Lai R, Aggarwal BB. Curcumin (diferuloylmethane)
carcinoma. Cancer Lett 2006;240:157-69. inhibits constitutive NF-kappaB activation, induces G1/S arrest,
16. Wong CM, Ng IO. Molecular pathogenesis of hepatocellular carcinoma. suppresses proliferation, and induces apoptosis in mantle cell lymphoma.
Liver Int 2008;28:160-74. Biochem Pharmacol 2005;70:700-13.
17. Frau M, Biasi F, Feo F, Pascale RM. Prognostic markers and putative 36. Kamat AM, Sethi G, Aggarwal BB. Curcumin potentiates the apoptotic
therapeutic targets for hepatocellular carcinoma. Mol Aspects Med effects of chemotherapeutic agents and cytokines through down-regulation
2010;31:179-93. of nuclear factor-kappaB and nuclear factor-kappaB-regulated gene
18. Darvesh AS, Aggarwal BB, Bishayee A. Curcumin and liver cancer: a products in IFN-alpha-sensitive and IFN-alpha-resistant human bladder
review. Curr Pharm Biotechnol 2012;13:218-28. cancer cells. Mol Cancer Ther 2007;6:1022-30.
19. Lee JH, Kim HY, Kim YJ, Yoon JH, Chung JW, Lee HS. Barcelona Clinic 37. Li L, Aggarwal BB, Shishodia S, Abbruzzese J, Kurzrock R.
Liver Cancer staging system and survival of untreated hepatocellular Nuclear factor-kappaB and IkappaB kinase are constitutively
carcinoma in a hepatitis B virus endemic area. J Gastroenterol Hepatol active in human pancreatic cells, and their down-regulation by
2015;30:696-705. curcumin (diferuloylmethane) is associated with the suppression of
20. Takayasu K, Muramatsu Y, Moriyama N, Hasegawa H, Makuuchi M, proliferation and the induction of apoptosis. Cancer 2004;101:2351-62.
Okazaki N, Hirohashi S, Tsugane S. Clinical and radiologic assessments 38. Shakibaei M, Schulze-Tanzil G, John T, Mobasheri A. Curcumin protects
of the results of hepatectomy for small hepatocellular carcinoma and human chondrocytes from IL-l1beta-induced inhibition of collagen
therapeutic arterial embolization for postoperative recurrence. Cancer type II and beta1-integrin expression and activation of caspase-3: an
1989;64:1848-52. immunomorphological study. Ann Anat 2005;187:487-97.
21. Sato M, Watanabe Y, Ueda S, Iseki S, Abe Y, Sato N, Kimura S, Okubo K, 39. Skommer J, Wlodkowic D, Pelkonen J. Gene-expression profi ling during
Onji M. Microwave coagulation therapy for hepatocellular carcinoma. curcumin-induced apoptosis reveals downregulation of CXCR4. Exp
Gastroenterology 1996;110:1507-14. Hematol 2007;35:84-95.
22. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 40. Wang S, Yu S, Shi W, Ge L, Yu X, Fan J, Zhang J. Curcumin inhibits
2003;362:1907-17. the migration and invasion of mouse hepatoma Hca-F cells through
23. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, down-regulating caveolin-1 expression and epidermal growth factor
Montalto F, Ammatuna M, Morabito A, Gennari L. Liver transplantation receptor signaling. IUBMB Life 2011;63:775-82.
for the treatment of small hepatocellular carcinomas in patients with 41. Lin LI, Ke YF, Ko YC, Lin JK. Curcumin inhibits SK-Hep-1
cirrhosis. N Engl J Med 1996;334:693-9. hepatocellular carcinoma cell invasion in vitro and suppresses matrix
24. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de metalloproteinase-9 secretion. Oncology 1998;55:349-53.
Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, 42. Chiablaem K, Lirdprapamongkol K, Keeratichamroen S, Surarit R,
Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Svasti J. Curcumin suppresses vasculogenic mimicry capacity of
Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J; hepatocellular carcinoma cells through STAT3 and PI3K/AKT inhibition.
SHARP Investigators Study Group. Sorafenib in advanced hepatocellular Anti-cancer Res 2014;34:1857-64.
carcinoma. N Engl J Med 2008;359:378-90. 43. Shoji M, Nakagawa K, Watanabe A, Tsuduki T, Yamada T, Kuwahara S,
25. Je Y, Schutz FA, Choueiri TK. Risk of bleeding with vascular endothelial Kimura F, Miyazawa T. Comparison of the effects of curcumin and
growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: curcumin glucuronide in human hepatocellular carcinoma HepG2 cells.
a systematic review and meta-analysis of clinical trials. Lancet Oncol Food Chem 2014;151:126-32.
2009;10:967-74. 44. Bandyopadhyay D. Farmer to pharmacist: curcumin as an anti-invasive
26. Lu SC. Where are we in the chemoprevention of hepatocellular and anti-metastatic agent for the treatment of cancer. Front Chem
carcinoma? Hepatology 2010;51:734-6. 2014;2:113.
27. Dai XZ, Yin HT, Sun LF, Hu X, Zhou C, Zhou Y, Zhang W, Huang XE, 45. Bishayee A, Politis T, Darvesh AS. Resveratrol in the chemoprevention
Li XC. Potential therapeutic effi cacy of curcumin in liver cancer. Asian and treatment of hepatocellular carcinoma. Cancer Treat Rev
Pac J Cancer Prev 2013;14:3855-9. 2010;36:43-53.
28. Lin W, Zhao J, Cao Z, Zhuang Q, Zheng L, Cai Q, Chen D, Wang L, 46. Baur JA, Sinclair DA. Therapeutic potential of resveratrol: the in vivo
Hong Z, Peng J. Livistona chinensis seed suppresses hepatocellular evidence. Nat Rev Drug Discov 2006;5:493-506.
carcinoma growth through promotion of mitochondrial-dependent 47. Udenigwe CC, Ramprasath VR, Aluko RE, Jones PJ. Potential of
apoptosis. Oncol Rep 2013;29:1859-66. resveratrol in anti-cancer and anti-infl ammatory therapy. Nutr Rev
29. Xia JF, Gao JJ, Inagaki Y, Kokudo N, Nakata M, Tang W. Flavonoids as 2008;66:445-54.
potential anti-hepatocellular carcinoma agents: recent approaches using 48. Saiko P, Szakmary A, Jaeger W, Szekeres T. Resveratrol and its analogs:
HepG2 cell line. Drug Discov Ther 2013;7:1-8. defense against cancer, coronary disease and neurodegenerative maladies
30. Aggarwal BB, Harikumar KB. Potential therapeutic effects of curcumin, or just a fad? Mutat Res 2008;658:68-94.
the anti-infl ammatory agent, against neurodegenerative, cardiovascular, 49. Shankar S, Singh G, Srivastava RK. Chemoprevention by resveratrol:
pulmonary, metabolic, autoimmune and neoplastic diseases. Int J molecular mechanisms and therapeutic potential. Front Biosci
Biochem Cell Biol 2009;41:40-59. 2007;12:4839-54.
31. Sugiyama Y, Kawakishi S, Osawa T. Involvement of the beta-diketone 50. Das S, Das DK. Anti-infl ammatory responses of resveratrol. Infl amm
moiety in the anti-oxidative mechanism of tetrahydrocurcumin. Biochem Allergy Drug Targets 2007;6:168-73.
Pharmacol 1996;52:519-25. 51. Rubiolo JA, Mithieux G, Vega FV. Resveratrol protects primary rat
32. Singh S, Aggarwal BB. Activation of transcription factor NF-kappa B is hepatocytes against oxidative stress damage: activation of the Nrf2
suppressed by curcumin (diferuloylmethane) [corrected]. J Biol Chem transcription factor and augmented activities of anti-oxidant enzymes.
1995;270:24995-5000. Eur J Pharmacol 2008;591:66-72.
33. Libby P. Infl ammatory mechanisms: the molecular basis of infl ammation 52. Delmas D, Jannin B, Cherkaoui Malki M, Latruffe N. Inhibitory effect
and disease. Nutr Rev 2007;65:S140-6. of resveratrol on the proliferation of human and rat hepatic derived cell
34. Ralhan R, Pandey MK, Aggarwal BB. Nuclear factor-kappa B links lines. Oncol Rep 2000;7:847-52.

Hepatoma Research | Volume 1 | Issue 3 | October 15, 2015 123